Month: October 2017

Antibody Drug Conjugates: Riding on the Second Growth Wave

While there are close to 200 ADCs in various stages of development, the market field is currently going through a gradual transition, shifting from relying on conventional technologies to newer approaches for generating ADCs. The ‘Antibody Drug Conjugates Market (4th Edition), 2017-2030’ report provides a comprehensive study on the current landscape of ADCs, featuring an elaborate discussion

Biopharmaceutical Contract Manufacturing: Transforming Promise into Reality

The development and manufacturing processes for biologics are complex, and usually require advanced capabilities and specialized expertise. This has led many stakeholders in the biopharmaceutical industry to outsource significant parts of their business operations to contract service providers. The ‘Biopharmaceutical Contract Manufacturing Market (2nd edition), 2017 – 2027’ report provides an extensive study of the contract manufacturing

Antibody Discovery: The Rise of Services and Platform Providers

The rising demand for personalized medicines to provide targeted treatment options has encouraged pharmaceutical companies to shift their focus from small molecules to discovery and development of biologics, particularly antibody-based therapeutics. The ‘Antibody Discovery: Services and Platforms, 2017-2027’ report provides an extensive study on the current market landscape and future outlook of the antibody discovery service and

Modular Facilities in Pharma / Biotech: An Evolutionary Leap Forward

Modular facilities have demonstrated tremendous potential in several fields; specifically, the shorter time taken to establish such facilities has a significant impact on expediting various operational processes. The ‘Modular Facilities in the Pharmaceutical / Biotechnology Industry, 2017-2030’ report provides an extensive study on the current market landscape and future outlook of modular facility manufacturers that